Mumbai: In a ruling reinforcing the protection of pharmaceutical trademarks, the Bombay High Court has granted interim relief to Laboratories Griffon, restraining Adwin Pharma and its marketing partner Elcliff Formulations from using the allegedly deceptively similar trademark ELGIMET for their diabetes medication.

The order was delivered by Justice Sharmila U. Deshmukh in the Commercial Division of the Bombay High Court, after the matter was reserved for orders on 10 November 2025 and pronounced on 18 November 2025.

Laboratories Griffon, incorporated in 1947 and a long-established manufacturer of medicinal preparations, holds registered trademarks “GLIMET” (since 1992) and “GLIMET DS” (since 1999) for anti-diabetic drugs. The company recently discovered the sale of Adwin Pharma’s ELGIM

See Full Page